Search

Displaying results 1891 - 1900 of 10000 in total
  1. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    [A230088] Fosdenopterin was approved by the FDA on Februrary 26, 2021, for the reduction of mortality in patients with MoCD type A,[L32163] becoming the first and only therapy approved for the treatment … [A230088,A230593] In the past, management strategies for this disorder involved symptomatic and supportive treatment,[L32163] though efforts were made to develop a suitable exogenous replacement for the

  2. Drug

    Pafolacianine

    go.drugbank.com/drugs/DB15413
    ApprovedInvestigational

    [L39332] It is currently under investigation for use in FRα-positive pituitary adenoma, lung cancer,[A242577] and renal-cell carcinoma, which is thought to be the second-highest folate receptor-expressing … [A242572] On November 29, 2021, the FDA approved pafolacianine as an adjunct imaging agent for intraoperative identification of malignant lesions in adult patients with ovarian cancer.

    Categories: Compounds used in a research, industrial, or household setting
  3. Target

    Cell growth-regulating nucleolar protein

    go.drugbank.com/bio_entities/BE0008958
    TargetMouse

    Prevents NCL self-cleavage, maintaining a normal steady-state level of NCL protein in undifferentiated embryonic stem cells (ESCs), which in turn is essential for ESC self-renewal (PubMed:19489080). … In addition, inhibits NF-kappa-B-mediated expression of pro-inflammatory cytokines (By similarity).

    Synonyms: Protein expressed in male leptotene and zygotene spermatocytes 264
  4. Target

    Serine/threonine-protein kinase Nek3

    go.drugbank.com/bio_entities/BE0009497
    TargetHumans

    Regulates microtubule acetylation in neurons. Contributes to prolactin-mediated phosphorylation of PXN and VAV2. … Implicated in prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells through mechanisms involving RAC1 activation and phosphorylation of PXN and VAV2

    Synonyms: Never in mitosis A-related kinase 3
  5. Drug

    Lonafarnib

    go.drugbank.com/drugs/DB06448
    ApprovedInvestigational

    for localization to the nuclear membrane, lonafarnib inhibits progerin accumulation and improves symptoms in HGPS patients. … aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.

  6. Drug

    Spinosad

    go.drugbank.com/drugs/DB08823
    ApprovedVet approved

    to many investigations for use in other animals and agricultural plants. … Spinosad has also been experimented for use in cats for treatment of flea infestations, and has also been experimented for use against the KS1 Ctenocephalides felis flea strain infesting dogs, in addition

    Mixtures: Comfortis Plus (Spinosad + Milbemycin oxime) Chewable Tablets for Dogs 9.1-18kg, Comfortis Plus (Spinosad + Milbemycin oxime) Chewable Tablets for Dogs 18.1-27kgCategories: Compounds used in a research, industrial, or household setting
  7. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    Cushing's disease),[A191850] and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication.[L12162] … [A191910] As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery

  8. Drug

    Stiripentol

    go.drugbank.com/drugs/DB09118
    ApprovedInvestigational

    [A19739] Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit. … [A250825] However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs

  9. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    [A187361] Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and a gene that does not produce protein or … [A187361] While dual corrector/potentiator combination therapy has proven useful in the treatment of a subset of CF patients,[A187358] their use is typically limited to patients who are homozygous for

  10. Drug

    Padeliporfin

    go.drugbank.com/drugs/DB15575
    ApprovedInvestigational

    [A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799] … Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies.

    Categories: Sensitizers Used in Photodynamic/radiation Therapy, Heterocyclic Compounds with 4 or More Rings